Targeting MSR1+ tumor-associated macrophages enhances the therapeutic efficacy of anti-PD-L1 in hepatocellular carcinoma by suppressing NF-κB pathway activation

TAMs can overcome resistance to anti-PD-L1 therapy, offering a promising new immunotherapeutic approach for HCC.